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  23 
Synopsis 24 
Objectives: to characterize phenotypically and genotypically the first Enterococcus faecium 25 
clinical isolate harbouring a vanG operon.  26 
Methods: The antibiotic-resistance profile of E. faecium 16-346 was determined and its 27 
whole genome sequenced using the PacBio technology. Attempts to transfer vancomycin 28 
resistance by filter mating were performed and the inducibility of expression of the vanG 29 
operon was studied by reverse-transcription quantitative PCR (RT-qPCR) in the presence or 30 
absence of subinhibitory concentrations of vancomycin. 31 
Results: E. faecium 16-346 was resistant to rifampicin (Minimum Inhibitory Concentration 32 
(MIC) > 4 mg/L) erythromycin (MIC > 4 mg/L), tetracycline (MIC > 16 mg/L) and 33 
vancomycin (MIC of 8 mg/L) but susceptible to teicoplanin (MIC of 0.5 mg/L). The strain 34 
harboured the vanG operon into its chromosome, integrated into a 45.5-kb putative mobile 35 
genetic element, similar to that of E. faecalis BM4518. We were unable to transfer 36 
vancomycin resistance from E. faecium 16-346 to E. faecium BM4107 and E. faecalis JH2-2. 37 
Lastly, transcription of the vanG gene was inducible by vancomycin.  38 
Conclusions: This is to the best of our knowledge the first report of a VanG-type 39 
vancomycin-resistant strain of E. faecium. Despite the alarm pulled because of the therapeutic 40 
problems caused by vancomycin-resistant enterococci, our work shows that new resistant loci 41 
can still be found in E. faecium.  42 
  43 
Introduction 44 
Commensal bacteria of the human gut microbiota, enterococci have become major 45 
opportunistic pathogens.1 In addition, vancomycin-resistant Enterococcus faecium (VREF) is 46 
currently a member of the list of bacteria recently edited by the World Health Organization 47 
(WHO), for which new antibiotics are urgently needed 48 
(http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/). This 49 
points to the worldwide emergence of this species, especially hospital-adapted strains 50 
belonging to clonal complex (CC) 17, that leads to major concerns in clinical settings.2 51 
Glycopeptide resistance is due to the presence of van operons that encode enzymes catalyzing 52 
the production of modified peptidoglycan precursors ending in D-Ala-D-Lac (VanA, B, D and 53 
M) or D-Ala-D-Ser (VanC, E, G, L and N).2 These precursors have much less affinity for 54 
vancomycin than the D-Ala-D-Ala motif, leading to a resistant phenotype (MIC of 55 
vancomycin > 4 mg/L).2 Moreover, these operons are tightly regulated by VanS/VanR-type 56 
two-component system, where VanS is a membrane-bound histidine kinase and VanR a 57 
transcriptional regulator.3 Because some van operons are part of mobile genetic elements, the 58 
glycopeptide resistance has spread among enterococci.  59 
The vanG operon, in which the VanG ligase allows synthesis of precursor ending in D-Ala-D-60 
Ser, has only been detected in a few Enterococcus faecalis clinical isolates and confers 61 
moderate levels of resistance to vancomycin (MIC of 16 mg/L) but not to teicoplanin.4,5 It is 62 
characterized by a “three component” regulatory system comprising an additional repressor 63 
(VanUG) also involved in the control of the vanG operon transcription.6 64 
We report, to the best of our knowledge, the first clinical isolate of E. faecium harbouring a 65 
vanG operon. The genome of this strain (E. faecium 16-346) was completely sequenced and 66 
we identified in the chromosome an acquired putative mobile genetic element containing the 67 
vanG locus.  68 
 69 
Materials and methods 70 
Bacterial strains and MIC determination  71 
E. faecium 16-346 was obtained in 2016 from a fecal sample of a non-infected 40-year-old 72 
female patient hospitalized in the medical center of Sainte-Foy-l’Argentière, France.  73 
E. faecium BM4107 and E. faecalis JH2-2 were used for filter mating experiments. 74 
MICs of 20 antibiotics (chloramphenicol, daptomycin, gentamicin, linezolid, rifampicin, 75 
trimethoprim/sulfamethoxazole, quinupristin/dalfopristin, tetracycline, erythromycin, 76 
oxacillin, ampicillin, penicillin G, vancomycin, levofloxacin, tigecycline, moxifloxacin, 77 
clindamycin, streptomycin, ciprofloxacin and nitrofurantoin) were determined using a 78 
SensititreTM automated system (Thermo Fisher Scientific, Waltham, MA, USA) according to 79 
the manufacturer’s instructions.  80 
 81 
Whole genome sequencing and accession number 82 
The whole genome sequence of the E. faecium 16-346 strain was determined with the PacBio 83 
technology (GATC Biotech, Konstanz, Germany). The sequence was annotated using the 84 
NCBI Prokaryotic Genome Annotation Pipeline.7 The sequence was submitted to GenBank 85 
and assigned accession no. CP021849. 86 
 87 
Filter mating 88 
Transfer of vancomycin resistance from E. faecium 16-346 to E. faecium BM4107 and E. 89 
faecalis JH2-2 was attempted by filter mating. Transconjugants were selected on brain heart 90 
infusion (BHI) agar containing rifampicin (60 mg/L), fusidic acid (50 mg/L) and vancomycin 91 
(4 mg/L). 92 
 93 
Reverse-transcription quantitative PCR (RT-qPCR) experiments 94 
The expression of the vanG gene was assessed by RT-qPCR using RNAs extracted from 95 
bacterial cells (OD600 of 0.5) grown in the absence or in the presence of subinhibitory 96 
concentrations of vancomycin (i.e., 1 or 2 mg/L). PCR amplification was carried out with 97 
primers specific for vanG (vanG-F: (5’-TTCGTGCAGGCTCTTCCTTT-3’; vanG-R: 5’-98 
CACAACCGACTTCAAAGCCG-3’) or adk (housekeeping reference-gene) as described.8  99 
 100 
Results and discussion 101 
Characterization of E. faecium 16-346  102 
E. faecium 16-346 was resistant to vancomycin (MIC of 8 mg/L). It was also resistant to 103 
rifampicin (MIC > 4 mg/L), erythromycin (MIC > 4 mg/L), and tetracycline (MIC > 16 mg/L) 104 
but remained susceptible to teicoplanin (MIC of 0.5 mg/L) and to the other antibiotics tested. 105 
Screening by specific PCR for the presence of the vanA, vanB, vanD, vanM and vanN genes, 106 
known to confer glycopeptide resistance in this species was negative.2 Primers specific for the 107 
other van operons, not yet described in E. faecium were tested, and an amplification of the 108 
vanG gene was obtained. vanG-type operons have only been found in E. faecalis clinical 109 
isolates from Australia and Canada as well as in various Clostridium sp. 4,5,9,10 In the latter, 110 
vanG did not confer vancomycin resistance but they may however be considered as a possible 111 
reservoir. It has been shown that part of the microflora of the human gastrointestinal tract 112 
harboured the vanG gene.11 Indeed, from 248 rectal swabs samples, Domingo and coworkers 113 
showed that 9.3% were positive for vanG, but none was associated with enterococci.12 Since, 114 
to our knowledge, no VanG-type E. faecium have been identified so far, we further analyzed 115 
this strain by whole genome sequencing.  116 
With a size of 2,736,595 bp, the genome harboured 2,824 putative genes (2,730 CDS) (Figure 117 
S1). This strain was plasmid free and belonged to sequence type ST121. Search for resistance 118 
genes revealed the presence of the vanG operon, but also that of erm(Y) and msr(C), both 119 
involved in macrolide resistance, as well as that of tet(M) and tet(L) that confer tetracycline 120 
resistance (Table 1). These data were in agreement with the resistance phenotype of E. 121 
faecium 16-346.  122 
 123 
Analysis of the vanG operon 124 
The sequence of the vanG operon was very similar to those from E. faecalis BM4518, WCH9 125 
and G1-0247 (Figure 1).4,5,13 Indeed, the van genes (UG, RG, SG, YG, WG, GG, XYG, and TG) 126 
were between 98.6% and 100% identical (Table 1). Thus, after VanN, VanG is the second 127 
ligase able to synthetize D-Ala-D-Ser-ending precursors in E. faecium.14 This is consistent 128 
with low level vancomycin resistance (MICs of 8-16 mg/L), since the precursors ending with 129 
D-Ala-D-Ser present only a seven-fold less affinity for the antibiotic.15 In vanYG of E. faecalis 130 
BM4518, a frameshift mutation is present.13 In E. faecium, vanYG has no mutations as in the 131 
vanYG from E. faecalis G1-0247 strain.5 132 
Twenty two bp imperfect inverted repeats (IR) framed the mobile genetic element (Figure 1). 133 
In E. faecalis BM4518, the element is 240 kb long, whereas, in E. faecium, its size was of 134 
45.5 kb comprising 43 genes (Table S1). Of note, the sequence of the left IR was identical to 135 
that of E. faecalis G1-0247 (CGGTAGTACTTCTTTCCCACAA) and diverged from that of 136 
BM4518 by 2 bases (CGGTGGTACTGCTTTCCCACAA).5,13 Surprisingly, the sequence of 137 
the left direct repeat (DR) (TGGA) was not the same as the TTGA sequence of the right DR 138 
(Figure 1). Based on the sequence of E. faecium Aus0004, TGGA appears as the motif present 139 
into the gene in which the element has been inserted16. It may be hypothesized that the target 140 
site of integration could be only the GA 2-bp sequence. To date, in E. faecalis, two types of 141 
vanG operon have been characterized, one from strain BM4518, WCH9 and G1-0247 (vanG), 142 
and another from N03-0233 (vanG2), lacking the vanYG gene and showing also a 2-bp (CA) 143 
DR.5 Interestingly, in all the VanG-type strains (clinical isolates or transconjugants) insertion 144 
of the vanG cluster systematically occurred into the gene encoding a RNA methyltransferase, 145 
whereas the vanG2 is located into the dctP gene (encoding a subunits of the TRAP 146 
dicarboxylate transporter).13 This was not observed in E. faecium where the element was 147 
integrated into a gene encoding a hypothetical protein (annotated EFAU004_00391) (Figure 148 
1).  149 
 150 
Attempts to transfer and inductibility of expression of the vanG operon 151 
We were unable to transfer vancomycin resistance from E. faecium 16-346 to E. faecium 152 
BM4107 and E. faecalis JH2-2. Similarly, McKessar and co-workers failed to transfer vanG 153 
operons from E. faecalis to E. faecium.4 In E. faecalis BM4518, erm(B) was co-transferred 154 
with vanG and transconjugants could only be obtained on erythromycin-containing plates.13 155 
In E. faecium 16-346, the mobile genetic element did not harbour erm(B) and macrolide 156 
resistance was likely due to the presence of the erm(Y) and msr(C) genes located 231 kb and 157 
522 kb downstream, respectively (Table 1). As in E. faecalis G1-0247 and N03-0233, the 158 
functions necessary for the transfer should not efficient or the experimental conditions were 159 
not adapted. 160 
In order to test if vanG expression was inducible, RT-qPCR experiments were carried out 161 
from cells grown with 0, 1 or 2 mg/L of vancomycin (corresponding to 1/8 and ¼ of MIC, 162 
respectively). As expected, vanG transcription was increased 3 and 5 fold (p<0.05) in the 163 
presence of 1 and 2 mg/L of antibiotic, respectively. This strongly suggests that 164 
transcriptional regulation may be similar to that of E. faecalis where the repressor VanUG and 165 
the activator VanRG (both present in E. faecium) compete to the same PYG promoter leading to 166 
a rheostatic control of vanG operon expression.6 167 
 168 
Conclusion 169 
To our knowledge, this is the first report of a vanG-type locus acquired by a strain of E. 170 
faecium. This points out that the surveillance of VREF remains crucial to overcome the spread 171 
of this major opportunistic pathogen.  172 
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 223 
Table 1: Antimicrobial-resistance genes identified in the genome sequence of E. faecium 16-224 
246. 225 
 226 
 
Gene 
 
% Identity 
 
Position in contig 
 
Phenotype 
 
Accession no. 
 
vanTG 100.00a 1442739..1444877 Vancomycin resistance  AY271782 
vanXYG 100.00a 1444870..1445634 Vancomycin resistance  AY271782 
vanG 100.00a 1445631..1446680 Vancomycin resistance  AY271782 
vanWG 99.88a 1446682..1447527 Vancomycin resistance  AY271782 
vanYG 100.00b 1447603..1448442 Vancomycin resistance  DQ212986 
vanSG 99.82a 1448579..1449683 Vancomycin resistance  AY271782 
vanRG 100.00a 1449697..1450404 Vancomycin resistance AY271782 
vanUG 100.00a 1450406..1450633 Vancomycin resistance  AY271782 
tet(M) 97.45c 1707444..1709362 Tetracycline resistance EU182585 
tet(L) 99.85d 1709491..1710832 Tetracycline resistance M29725 
erm(Y) 81.51e 1715249..1715977 Macrolide resistance AB014481 
msr(C) 98.99f 2006190..2007668 Macrolide, Lincosamide 
Streptogramin resistance 
AY004350 
    
aIdentity with the homologous gene from E. faecalis BM4518 227 
bIdentity with the homologous gene from E. faecalis G1-0247 228 
cIdentity with the homologous gene from Streptococcus suis T2S3 229 
dIdentity with the homologous gene from pLS1 plasmid of Streptococcus agalactiae  230 
eIdentity with the homologous gene from the pMS97 plasmid of Staphylococcus aureus RN4220  231 
fIdentity with the homologous gene from E. faecium TX2465 232 
  233 
Legends  234 
 235 
 236 
Figure 1: Schematic of the chromosome region harbouring the vanG operon of E. faecium 16-237 
346, compared to the corresponding region of E. faecalis BM4518.  238 
DR-L, direct repeat left; DR-R, direct repeat right; IR-L, inverted repeat left; IR-R, inverted 239 
repeat right.  240 
 241 
Table S1: Genes identified in the mobile genetic element containing the vanG operon in E. 242 
faecium 16-346.  243 
 244 
Figure S1: Circle representation of the genome of E. faecium 16-346 compared to four other 245 
E. faecium genomes.  246 
 247 
 248 
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 250 
